Adamas Pharmaceuticals Receives Orphan Drug Designation for ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia Associated With Parkinson’s Disease

Industry News

Adamas Pharmaceuticals, based in Emeryville, CA announced that the FDA has granted Orphan Drug Designation (ODD) for ADS-5120 for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease (PD).  ADS-5120 is a high dose, extended-release formula of amantadine HCl that is administered once daily at bedtime.  LID is a complication that induced by long-term treatment with levodopa, the most widely used medicine to treatment of PD.  Currently, there is no approved drug available to treat LID.  Previous Phase II/III studies with ADS-5120 have shown positive results and Adamas is sponsoring multiple phase III clinical trials evaluating its efficacy in PD patients with LID.


Original Article:

Subscribe to WXPress

Receive our newsletter and information on upcoming events.